Physician profile
Daniel Mulligan
NPI 1851581888
$640.95
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $370.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $238.40 | 2019-2020 | |
| Boston Scientific Corporation | $195.72 | 2019-2020 | |
| Neotract INC. | $80.16 | 2020 | |
| Intuitive Surgical, INC. | $55.34 | 2019 | |
| Endo Pharmaceuticals INC. | $38.44 | 2019-2020 | |
| Abbvie INC. | $28.32 | 2019-2020 | |
| Hitachi Healthcare Americas Corp. | $4.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mulligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.